Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1

AIDS Research and Human Retroviruses

Volumn 14, Issue 6, 1998, Pages 475-481

  Hengel, Richard L ^a,b   Kennedy, M Susan ^b   Steketee, Richard W ^c   Thea, Donald M ^d   Abrams, Elaine J ^e   Lambert, Genevieve ^f   McDougal, J Steven ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Medical and Health Research Association   (United States)

^e HARLEM HOSPITAL CENTER   (United States)

^f BRONX LEBANON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN; PERINATAL INFECTION; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 0032502653     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.475     Document Type: Article

References (40)

1. Dabis F, Msellati P, Dunn D, Lepage P, Newell ML, Peckham C, and Van dePerre P: Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues Ghent (Belgium), 17-20 February 1992. The Working Group on Mother-to-Child Transmission of HIV. AIDS 1993;7:1139-1148.
2. Boyer P, Dillon M, Navaie M, Deveikis A, Keller M, O'Rourke S, and Bryson Y: Factors predictive of maternal-fetal transmission of HIV-1. JAMA 1994;271:1925-1930.
3. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ, Deveikis A, Stiehm ER, and Bryson YJ: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
4. St. Louis ME, Kamenga M, Brown C, Nelson AM, Manzila T, Batter V, Kabagabo U, Ryder RW, Oxtoby M, Quinn TC, and Heyward WL: Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993;269:2853-2859.
5. Mayaux MJ, Blanche S, Rouzioux C, Le Chenadec J, Chambrin V, Firtion G, Allemon MC, Vilmer E, Vigneron NC, Tricoire J, Guillot F, Courpotin C, and the French Pediatric HIV Infection Study Group: Maternal factors associated with perinatal HIV-1 transmission: The French Cohort Study: 7 years of follow-up observation. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:188-194.
6. Weiser B, Nachman S, Tropper P, Viscosi KH, Grimson R, Baxter G, Fang G, Reyelt C, Hutcheon N, and Burger H: Quantitation of human immunodeficiency virus type 1 during pregnancy: Relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA 1994;91:8037-8041.
7. Scarlatti G, Hodara V, Rossi P, Muggiasca L, Bucceri A, Albert J, and Fenyö EM: Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 1993;197:624-629.
8. De Rossi A, Giaquinto C, Ometto L, Mammano F, Zanotto C, and Dunn D: Replication and tropism of human immunodeficiency virus type 1 as predictors of disease outcome in infants with vertically acquired infection. J Pediatr 1993;123:929-936.
9. Kliks S, Wara DW, Landers DV, and Levy JA: Features of HIV-1 that could influence maternal-child transmission. JAMA 1994;272:467-474.
10. Ometto L, Zanotto C, Maccabruni A, Caselli D, Truscia D, Giaquinto CR, Chieco-Bianchi L, and De Rossi A: Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS 1995;9:427-434.
11. Abrams EJ, Matheson PB, Thomas PA, Thea DM, Krasinski K, Lambert G, Bamji M, Hutson D, Grimm K, Kaul A, Bateman D, Rogers M, and the New York City Perinatal HIV Transmission Colloborative Study Group: Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. New York City Perinatal HIV Transmission Collaborative Study Group. Pediatrics 1995;96(3 Pt 1):451-458.
12. Goedert JJ, Duliege AM, Amos CI, Felton S, and Biggar RJ: High risk of HIV-1 infection for first-born twins. The International Registry of HIV-Exposed Twins. Lancet 1992;338:1471-1475.
13. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, and Fenyö EM: Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993;168:207-210.
14. Semba RD, Miotti PG, Chiphangwi JD, Saah AJ, Canner JK, Dallabetta GA, and Hoover DR: Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994;343:1593-1597.
15. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, and Sullivan JL: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996;335:1621-1629.
16. Pitt J, Brambilla D, Reichelderfer P, Landay A, McIntosh K, Burns D, Hillyer GV, Mendez H, and Fowler MG: Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection - findings from the Women and Infants Transmission Study. J Infect Dis 1997;175:567-575.
17. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, and McIntosh K: Vertical transmission of human immunodeficiency virus type 1: Autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 1995;126:865-871.
18. Jenkins M, Landers D, Williams-Herman D, Wara D, Viscarello RR, Kline MW, Shearer WT, Charlebois ED, and Kohl S: Association between anti-human immunodeficiency virus type 1 (HIV-1) antibody-dependent cellular cytotoxicity antibody titers at birth and vertical transmission of HIV-1. J Infect Dis 1994;170:308-312.
19. Mabondzo A, Rouvier P, Raoul H, Le Naour R, Courpotin C, Herve F, Lasfargues G, and Dormont D: Relationships between humoral factors in HIV-1-infected mothers and the occurrence of HIV infection in their infants. Clin Exp Immunol 1995;102:476-480.
20. Thea DM, Steketee RW, Bornshlegel K, Pliner V, Brown T, Matheson PB, Abrams EJ, Bamji M, Lambert G, Schoenbaum EA, Thomas PA, Heagarty M, Kalish M, and the New York City Perinatal HIV Transmission Colloborative Study Group: The effect of maternal viral load on the risk of perinatal transmission of HVI-1. J Infect Dis 1997;175:707-711.
21. Scarlatti G, Lombardi V, Plebani A, Principi N, Vegni C, Ferraris G, Bucceri A, Fenyö EM, Wigzell H, Rossi P, and Albert J: Polymerase chain reaction, virus isolation and antigen assay in HIV-1 antibody-positive mothers and their children. AIDS 1991;5:1173-1178.
22. McDougal JS, Kennedy MS, Orloff SL, Nicholson JKA, and Spira TS: Mechanisms of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol 1996;70:5236-5245.
23. McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorino PM Francis DP, Hicks D, Kalyanaraman VS, and Martin LS: Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods 1985;76:171-183.
24. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rubsamen-Waigmann H, and Mullins JI: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
25. Orloff GM, Orloff SL, Kennedy MS, Maddon PJ, and McDougal JS: Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry. J Immunol 1991;146:2578-2587.
26. Centers for Disease Control and Prevention: 1997 Revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR 1997;46(No. RR-2):1-29.
27. Montefiori DC, Zhou J, Barnes B, Lake D, Hersh EM, Masuho Y, and Lefkowitz LB Jr: Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 1991;182: 635-443.
28. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, and Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:211-219.
29. Ugen K, Goedert J, Boyer J, Fefaili Y, Frank I, Williams W, Willoughby A, Landesman S, Mendez H, Rubinstein A, Kieber-Emmons T, and Weiner D: Vertical transmission of human immunodeficiency virus (HIV) infection. J Clin Invest 1992;89: 1923-1930.
30. Goedert JJ and Dublin S: Perinatal transmission of HIV type 1: Associations with maternal anti-HIV serological reactivity. Mothers and Infants Cohort Study and the HIV-1 Perinatal Serology Working Group. AIDS Res Hum Retroviruses 1994;1025:1125-1134.
31. Rubinstein A, Goldstein H, Calvelli T, Devash Y, Rubinstein R, Soeiro R, and Lyman W: Maternofetal transmission of human immunodeficiency virus-1: The role of antibodies to the V3 primary neutralizing domain. Pediatric Research 1993;33(Suppl. 1):S76-S78.
32. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, and Nielsen JO: Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr Hum Retrovirol 1992;5:303-307.
33. McDougal JS, Kennedy MS, Nicholson JKA, Spira TJ, Jaffe HW, Kaplan JE, Fishbein DB, O'Malley P, Aloisio C, Black CM, Hubbard M, and Reimer CB: Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency and disease progression. J Clin Invest 1987;80:316-324.
34. Cao YZ, Friedman-Kien AE, Mirabile M, Li XL, Alam M, Dieterich D, and Ho DD: HIV-1 neutralizing antibodies in urine from seropositive individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1990;3:195-199.
35. Robert-Guroff M, Roilides E, Muldoon R, Venson D, Husson R, Marshall D, Gallo RC, and Pizzo PA: Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: Correlation with clinical status and prognostic value. J Infect Dis 1993;167:538-546.
36. Robert-Guroff M, Goedert JJ, Naugle CJ, Jennings AM, and Blattner WA: Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: Results of a 6 year prospective study. AIDS Res Hum Retroviruses 1988;4:343-350.
37. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kinglsey LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1124-1125.
38. Contag CH, Ehrnst A, Duda J, Bohlin AB, Lindgren S, Learn GH, and Mullins JI: Mother-to-infant transmission of human immunodeficiency virus type 1 involving five envelope sequence subtypes. J Virol 1997;71:1292-1300.
39. Wolinsky SM, Wike CM, Korber BTM, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtako MR, and Munoz JL: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992;255:1134-1137.
40. Ahmad N, Baroudy BM, Baker RC, and Chappey C: Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995;69:1001-1012.